Taken together, this emergence of PARP1 and other members of the ART family in the regulation of immune pathways underscores the immense potential for the further exploitation of these enzymes not only in cancer therapy but also in the treatment of immune-mediated diseases. This evidence concerns the gene PARP1 and cancer.